- Resource Centers
In a multinational, placebo-controlled trial, rosuvastatin proved to be well-tolerated in patients with dyslipidemia. The 33-trial program included >16,800 patients who represented >25,000 patient-years of continuous exposure to rosuvastatin. The patients received 5 to 40 mg of the drug or placebo. Adverse events occurred in 52.1% of the rosuvastatin group and 51.8% of the placebo group, giving it an adverse-event profile similar to that of atorvastatin 10 to 80 mg, simvastatin 10 to 80 mg, and pravastatin 10 to 40 mg.